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Abstract
Purpose The aim of our study was the evaluation of HE4
usefulness as a test in assessment of ovarian tumors which
are suspicious and difficult to classify correctly via sub-
jective ultrasound examination.
Methods In this retrospective cohort study 253 women
diagnosed with adnexal masses were examined preopera-
tively. Suspicious tumors (n = 145) were divided into
groups of: ‘‘probably benign’’ (n = 70), ‘‘uncertain’’
(n = 34), and ‘‘probably malignant’’ (n = 41). ‘‘Uncer-
tain’’ tumors were also assessed as ‘‘benign’’ (n = 11) or
‘‘malignant’’ (n = 23). The logistic regression model was
performed to analyze if the serum marker improves the
prediction of a malignant finding and net reclassification
improvement (NRI) was calculated to measure diagnostic
improvement.
Results Within the analyzed group 85 (58.6 %) benign
and 60 (41.4 %) malignant tumors were confirmed hist-
opathologically. The comparison of HE4 with subjective
ultrasound assessment showed lowered NRI in the entire
analyzed group as well as in the groups of tumors classified
as ‘‘probably benign’’ or ‘‘probably malignant’’ (NRI =
-0.16; P = 0.0139 and NRI = -0.133; P = 0.0489,
respectively). The analysis of logistic regression model
confirmed that biomarkers do not improve diagnostic
accuracy. The difference between areas under ROC for
HE4 (0.891) and CA125 (0.902) was not statistically sig-
nificant (P = 0.760).
Conclusions After subjective ultrasound assessment, the
addition of the second-line test—HE4 as well as CA125
serum level does not improve diagnostic performance.
However, HE4 evaluation satisfies the clinical expectations
of diagnostic tools for ovarian tumors and, thus, may be
useful to less experienced sonographers.
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Introduction
Epithelial ovarian cancer (EOC) remains one of the most
challenging problems in contemporary gynecological
oncology worldwide. Its high incidence and the fact that it
is especially an important cause of mortality among
malignant diseases make the problems of EOC diagnosis
and treatment very important. Research concerns the
elaboration of effective screening programs and methods
for early selection of women with ovarian cancer in pre-
clinical stage [1]. It also focuses on helpful methods for
preoperative malignancy prediction. If preoperative risk of
malignancy is high, it is crucial to refer patients to gyne-
cological oncology centers for surgical treatment, because
the prognosis is better there [2].
Currently, transvaginal ultrasonography is the most
effective method for prediction of malignancy. There are
opinions that the subjective assessment of an experienced
ultrasound examiner with a good quality ultrasound device
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can distinguish most benign and malignant ovarian tumors
[3–6]. Mathematical models and morphological indices are
also useful [7, 8]. Validation of the best mathematical
models with comparison to the ‘‘pattern recognition’’ used
by an expert sonographer confirms that the best diagnostic
method is subjective assessment of the tumor, although the
differences are not large [4]. But still a group of suspicious
tumors which are difficult to classify correctly requires
second-line tests [9, 10]. Improvement of this classification
may be achieved by the assessment of biochemical mark-
ers. CA125 is commonly used, but is far from ideal [11].
The main drawbacks of CA125 are low sensitivity, speci-
ficity, and the risk of false-positive results in non-EOC
malignant tumors as well as in benign conditions [12].
Furthermore, Valentin et al. [13] have shown that adding
the CA125 measurement to ultrasonography assessment
does not improve the accuracy of differential diagnosis of
adnexal masses. In 2003, a novel serum biomarker HE4
was proposed as either a first- or a second-line screen for
EOC and was registered for monitoring the disease status
in women with ovarian cancer [1, 14]. HE4 is an 11–13kD
protein that is a precursor to the human epididymal
secretory protein E4. It is a member of the family of stable
4-disulfide core proteins [14]. Recently many markers were
described in ovarian cancer diagnosis; however, in our
opinion HE4 seems to be the most promising among them.
HE4 in literature has been assessed as being a more specific
marker than CA125 alone, and as very helpful in combi-
nation with CA125 for risk of malignancy prediction
[15, 16].
The aim of our study was the evaluation of HE4’s
usefulness as a test in assessment of ovarian tumors which
are suspicious in a preoperative analysis by subjective
ultrasound examination.
Materials and methods
In this retrospective cohort study 253 consecutive women
diagnosed with adnexal masses were examined preopera-
tively with transvaginal ultrasonography by one experi-
enced sonographist, between 2005 and 2011 in a tertiary
gynecological oncology centre. The ultrasound examina-
tion was performed using an Aloka 3500 with a 7.5 MHz
endovaginal probe and additionally with a transabdominal
probe in large tumors. According to international ovarian
tumor analysis (IOTA) guidelines, the examiner performed
a subjective assessment of the risk of malignancy of any
tumor [17]. Tumors were classified as ‘‘certainly benign’’
(n = 84), ‘‘probably benign’’ (n = 70), ‘‘uncertain’’
(n = 34), ‘‘probably malignant’’ (n = 41), and ‘‘certainly
malignant’’ (n = 24). Tumors estimated to be ‘‘certainly
benign’’ or ‘‘certainly malignant’’ were excluded, while the
rest of the tumors were termed as ‘‘suspicious’’ tumors and
included for further analysis. Subsequently, ‘‘suspicious’’
tumors were again classified as ‘‘benign’’ (n = 81) or
‘‘malignant’’ (n = 64) in a final subjective ultrasound
assessment. Thus, the tumors classified as ‘‘uncertain’’ in
the first evaluation, were secondly classified as ‘‘benign’’ or
‘‘malignant’’. Whereas ‘‘probably benign’’ tumors were
subsequently classified as ‘‘benign’’, while ‘‘probably
malignant’’ were regarded as ‘‘malignant’’. The diagnostic
algorithm of subjective ultrasound classification of the risk
of malignancy of analyzed tumors is presented in Fig. 1. In
general, the examiner judged unilocular and multilocular
cysts without any papillary projection, even if smaller than
3 mm, or solid components to be benign. In some cases,
specific diagnosis was possible (e.g., endometrioma, tera-
toma, etc.,) based on ‘‘pattern recognition’’ of the gray-
scale ultrasound image and those tumors were classified as
‘‘certainly benign’’. Cystic tumors with solid components
and more complex, irregular tumors were judged to be
malignant.
Tumors of borderline malignancy (Low Malignancy
Potential, LMP) and metastatic adnexal tumors were clas-
sified as malignant adnexal masses.
Prior to operation, sera were collected for the determi-
nation of tumor markers HE4 and CA125 levels. HE4
serum levels were analyzed by EIA assay (Fujirebio
Diagnostics AB Go¨teborg, Sweden). CA125 serum levels
were assessed by immunoenzymatic test, ST AIA-PACK
OVCA TOSOH Japan. We assessed the utility of CA125 in
diagnosis of ovarian tumors with the use of two deferent
cut-offs: the standard cut-off used in our hospital—35 IU/
ml and the best cut-off calculated in the present study.
The usefulness of HE4 and CA125 assessment was
estimated using the analysis of receiver-operating charac-
teristics curves (ROC Curve). The ROC curve for sub-
jective ultrasonographic assessment was calculated with
the use of four levels of diagnostic confidence (‘‘probably
benign’’, ‘‘uncertain, finally classified as benign’’, ‘‘uncer-
tain, finally classified as malignant’’ and ‘‘probably
malignant’’). ROC curves were constructed using Med-
Calc, version 10.4.0.0 computer software.
Net reclassification improvement (NRI), which assesses
risk reclassification and is a measure of diagnostic
improvement, was calculated based on the published for-
mula [18]. There is a growing body of evidence that leads
to recommendations for the application of NRI in research
on new biomarkers introduced in clinical practice [19].
NRI enables the quantification of improvement of classi-
fication of events/non-events (e.g., ‘‘malignant’’, ‘‘non-
malignant’’ tumors) offered by new markers. Hence, the
reclassification tables, which NRI focuses on, are con-
structed separately for subjects with and without events.
Thus, NRI quantifies the correct movement in categories
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i.e., upwards for events and downwards for non-events. We
calculated the NRI for each marker (HE4, CA125 at 35 and
95 IU/ml cut-off) as an addition to the subjective assess-
ment of the entire analyzed group, and separately for
tumors classified as ‘‘probably malignant’’ or ‘‘probably
benign’’ and for ‘‘uncertain’’ tumors. In addition, NRI was
used to determine the contribution of HE4 analysis to
CA125 assessment. Furthermore, the logistic regression
model including subjective ultrasound assessment with the
addition of HE4 and CA125 was conducted.
Statistical analyses were conducted using Statistica for
Windows ver. 6.1 (Statsoft, USA) PQStat ver 1.4.6 (PQStat
Software, Poland). In the present study, the range was
defined as a minimal and maximal value.
The study received ethics approval (05.2005) and all
patients signed consent forms.
Results
Within the analyzed group of 145 women 85 (58.6 %)
benign and 60 (41.4 %) malignant tumors were confirmed
histopathologically. Eleven LMP tumors were included in
the malignant tumors group. The histological classification
of benign and malignant tumors is presented in Table 1.
Malignant tumors were classified according to the FIGO
stage of the disease as follows: I stage, 19 patients; II stage,
6 patients; and III stage, 35 patients.
The mean age of the patients studied was 47 years
(range 15–84 years). The mean age was 41.7 years (range
15–74 years) and 54.6 years (range 21–84 years) for the
patients with benign and malignant tumors, respectively.
Eighty-four (57.9 %) patients were premenopausal, while
61 (42.1 %) patients were postmenopausal.
Median tumor volume was 497 cm3 (range
17–4,187 cm3) and 101 cm3 (range 13–4,017 cm3) in the
malignant and benign tumor groups, respectively. The so-
nographic structure of the tumors analyzed is presented in
Table 2.
The median serum concentration of HE4 in all benign
tumors was 32.7 pmol/l (range 18.9–157.0) and in all
malignant tumors was significantly (P \ 0.001) higher, at
a level of 183.5 pmol/l (range 19.3–4,246.7). If the sub-
group of LMP tumors was separated, median HE4 con-
centrations in malignant and LMP tumors were
significantly different (P \ 0.001), 329.8 pmol/l (range
35.9–4,246.7) and 39.8 pmol/l (range 19.3–90.3), respec-
tively. Whereas, the differences between HE4 concentra-
tions in benign and LMP tumors were not statistically
significant (P [ 0.05).
The median serum concentration of CA125 in all
malignant tumors was 650.4 IU/ml (range 9.0–3,657.0) and
it was significantly (P \ 0.001) higher than in all benign
tumors, 21.1 IU/ml (range 4.2–525.1). In the subgroup of
LMP tumors, the median for malignant and LMP tumor
CA125 levels differed significantly (P \ 0.01) (913.0 and
51.4 IU/ml, respectively). The difference in CA125 levels
between benign and LMP tumors was not statistically
significant (P [ 0.05).
The results of HE4 and CA125 serum levels in the
subgroups of patients according to FIGO classification are
presented in Table 3.
Fig. 1 The diagnostic
algorithm of subjective
ultrasound classification of the
risk of malignancy of analyzed
tumors
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The diagnostic usefulness of HE4 and CA125 serum
level assessment as single tests was compared based on the
area under ROC analysis (Fig. 2). The differences between
areas under ROC for HE4 and CA125 were not statistically
significant (P = 0.760). According to the ROC analysis,
the best cut-off for HE4 serum level was set at 65 pmol/l.
But, we realize that the sample size is very low to rec-
ommend general cut-offs. In our study the specificity
(91.7 %), accuracy (86.9 %) and positive predictive value
(87.3 %) of HE4 analysis were higher than in CA125
analysis, while sensitivity (80.0 %) was lower. Combina-
tion of HE4 and CA125, when either or both biomarkers’
serum concentrations were above the cut-off level was
characterized by AU ROC = 0.866 (95 % CI
0.798–0.918). HE4 has higher diagnostic values than
CA125, especially for its standard cut-off, 35 IU/ml. If the
cut-off of CA125 is set at a level of 95 IU/ml in the ana-
lyzed group of ‘‘suspicious’’ tumors it gives better diag-
nostic performance almost as good as HE4.
The prognostic values of subjective ultrasonography
assessment were very high, with sensitivity and specificity
of 93.3 and 90.6 %, respectively. The area under ROC was
0.920 (95 % CI 0.863–0.958). Areas under ROC for
CA125, 0.902 (95 % CI 0.840–0.946) and for HE4, 0.891
(95 % CI 0.827–0.937) were not as high as for subjective
ultrasonography analysis, but the differences were not
statistically significant (subjective assessment vs. HE4,
P = 0.226; subjective assessment vs. CA125 P = 0.490).
Similarly, the area under the ROC curve for the combi-
nation test composed of HE4 and CA125 (AU
ROC = 0.866) was not significantly lower than for sub-
jective assessment (P = 0.099). The prognostic values for
subjective assessment, HE4 and CA125 levels are pre-
sented in Table 4, while, Table 5 summarizes the results of
subjective ultrasonographic assessment.
The comparison of HE4 and CA125 (at both analyzed
cut-offs) with subjective ultrasound assessment showed
lowered NRI across all analyzed groups as well as in the
groups of tumors classified as ‘‘probably benign’’ or
‘‘probably malignant’’. However, in the group of tumors
classified as ‘‘uncertain’’, the improvement was not statis-
tically significant. The results are summarized in Table 6.
NRI calculated for discrimination between malignant and
benign tumors did not show significant improvement of the
Table 1 Histopathological
tumor characteristics
Tumor Premenopausal Postmenopausal All patients %
Benign
Simple/functional/hemorrhagic cyst 12 4 16 18.8
Endometrioma 23 1 24 28.2
Teratoma 14 3 17 20.0
Serous cystadenoma 3 3 6 7.1
Mucinous cystadenoma 4 5 9 10.6
Tubo-ovarian abscess 4 1 5 5.9
Fibrothecoma/fibroadenoma/Brenner’s tumor 2 4 6 7.1
Leiomyoma 1 1 2 2.3
Total 63 22 85 100
Malignant
Serous adenocarcinoma 6 19 25 41.7
Mucinous adenocarcinoma 0 2 2 3.3
Endometrioid adenocarcinoma 2 2 4 6.7
Clear cell adenocarcinoma 1 2 3 5.0
Undifferentiated carcinoma 6 6 12 20.0
Other 0 3 3 5.0
Serous cancer of LMP 3 0 3 5.0
Mucinous cancer of LMP 3 5 8 13.3
Total 21 39 60 100







Unilocular 13 (15.3) 2 (3.3) 15 (10.3)
Unilocular solid 18 (21.2) 4 (6.7) 22 (15.2)
Multilocular 20 (23.5) 5 (8.3) 25 (17.2)
Multilocular solid 25 (29.4) 36 (60) 61 (42.1)
Purely solid 7 (8.2) 13 (21.7) 20 (13.8)
Not classifiable 2 (2.4) 0 (0) 2 (1.4)
Total 85 (100) 60 (100) 145 (100)
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diagnosis when HE4 was compared with CA125
(NRI = -0.034, P = 0.973).
The analysis of logistic regression including ultrasono-
graphic assessment, CA125 and HE4 levels evaluation in
discrimination between malignant and benign ovarian
tumors, showed that only ultrasonography had significant
impact on developing model. In that model, subjective
ultrasonographic assessment correctly classified 93.3 % of
cases. The analysis of logistic regression model confirmed
that biomarkers do not improve diagnostic accuracy.
Discussion
In the present study, we have found a lack of clinical utility
of HE4 serum concentrations assessment in patients with
ovarian tumors which are suspicious and difficult to clas-
sify correctly in subjective ultrasonography examination
performed by an experienced examiner. Similar results
were obtained for CA125. However, in the group of
ovarian tumors included in the study, the HE4 assessment
was a more specific and accurate test compared to CA125.
The positive predictive value of HE4 estimation in our
study exceeded the precision rate of CA125, especially for
its standard cut-off.
Research concerned with ‘‘suspicious’’ ovarian tumors is
especially important, because in this group the risk of false
results in diagnostic tests is high. It is not very difficult to
assess tumors at an advanced stage of the disease and then
the decision to operate in an oncological center is obvious.
Similarly, it is easy to diagnose a simple cyst or other
tumors classified as ‘‘certainly benign’’. In this group, the
risk of malignancy is extremely low. This is why the most
important and interesting tumors are those which pose
problems in ultrasound evaluation. According to the IOTA
group’s recent publication by Valentin et al. [20], only
7–10 % of masses are suspicious and difficult to classify.
This concerns tumors which are completely ‘‘uncertain’’ as
whether they are malignant or benign in sonographic
assessment. In our research this was 13.4 % (34/253) of
tumors, but for the final analysis of ‘‘suspicious’’ masses
we also included tumors which were ‘‘probably malignant’’
and ‘‘probably benign’’, where the decision is in some way
uncertain as well. This is why the group of analyzed tumors
consisted of 57 % (145/253) of all patients diagnosed with
adnexal masses.
Valentin et al. [10] suggest that logistic regression
models do not solve diagnostic problems in suspicious
pelvic masses. Daemen et al. [9] suggest that in the group
Table 3 Median and range (minimum and maximum) of HE4 and CA125 serum levels according to FIGO classification
FIGO I (n = 19) FIGO II (n = 6) FIGO III (n = 35) P value
Median Range Median Range Median Range
HE4 [pmol/l] 49.2 19.3–4,000 470.6 67.6–1,222.6 333.5 42.3–4,246.7 I vs. II p \ 0.05
I vs. III p \ 0.001
II vs. III p [ 0.05
CA125 [IU/ml] 77.2 9.04–1,260.0 940.15 37.0–3,269.0 1,018.9 89.0–3,657.0 I vs. II p [ 0.05
I vs. III p \ 0.001
II vs. III p [ 0.05
Fig. 2 ROC curves for HE4 and CA125 among patients with ovarian
tumors
Table 4 Comparison of prognostic values of subjective assessment,
HE4 serum level, CA125 serum level in group of 145 ‘‘suspicious’’
ovarian tumors analyzed




93.3 90.6 87.5 95.1 91.7 0.923
HE4 80.0 91.7 87.3 86.7 86.9 0.891
CA125 (cut-off 35
IU/ml)
85.7 74.7 69.6 88.7 79.1 0.902
CA125 (cut-off 95
IU/ml)
78.6 91.7 86.3 86.5 86.4 0.902
Sens sensitivity, Spec specificity, PPV positive predictive value, NPV
negative predictive value, ACC accuracy, AU ROC area under ROC
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of tumors where an examiner is wholly uncertain about the
diagnosis, new tests may well help in better classification
of these patients. For this reason, we conducted the study
looking at the role of a novel ovarian cancer marker as a
second-line test.
Hellstro¨m et al. [14] investigated the HE4 protein in an
ELISA assay in ovarian cancer patients, benign ovarian dis-
eases, and health checks in 2003. They concluded that HE4 is
overexpressed in ovarian cancer patients and has comparable
sensitivity and specificity to CA125. The advantage of HE4 as
a biomarker was the better detection of early cases of ovarian
cancer where at 95 % specificity, sensitivity for HE4 and
CA125 were 86 and 71 %, respectively. In our analysis for all
FIGO stages for 95 % specificity, sensitivity for HE4 and
CA125 were 65.0 and 76.8 %, respectively.
Moore et al. [16] proposed a predictive model for cal-
culation of risk of ovarian cancer based on the combination
of HE4 and CA125 serum levels. This multicenter,
prospective study confirmed the clinical usefulness of the
proposed model for the entire group of patients and also
subgroups of premenopausal and, especially, postmeno-
pausal women. The Risk of Ovarian Malignancy Algorithm
(ROMA) has been tested in several clinical trials [15, 16].
Van Gorp et al. [21] performed a prospective validation of
ROMA, HE4 and CA125 assessments and concluded that
neither of these tests are better than CA125. Contrary
considerations were presented by Molina et al. [15] who
noticed that HE4 is more specific than CA125 and has at
least the same sensitivity as CA125. In that paper, Molina
et al. [15] also noted that the level of false-positive CA125
results is high, especially in premenopausal women. In
another paper presented by Van Gorp et al. [22], the
authors suggest that subjective ultrasound assessment has
the highest area under the ROC = 0.968, and is better than
the risk of malignancy index (0.931) and ROMA (0.893)
both in pre- and in postmenopausal women. Those authors
concluded that subjective assessment by ultrasound
remains superior in discriminating malignant from benign
ovarian masses. Our data are similar with these findings,
where AU ROC for subjective ultrasound was 0.923 and
for combination of HE4 and CA125, 0.866 (P = 0.099).
According to the results presented in our study, we
conclude that subjective assessment was the best, as far as
the current state of the art for all tests under comparison is
concerned. Therefore, the training of ultrasound specialists,
using the most experienced persons to scan patients pre-
operatively, is the main prerequisite for the maintaining the
largest available accuracy in the diagnostics and quality of
scanning of adnexal masses. This opinion is also presented
by Timmerman et al. [3]. Also Franchi et al. [23] report, in
a multicenter prospective study of 174 women with
adnexal masses, that ultrasound expertise remains superior
in discriminating malignant masses in comparison with the
ROMA algorithm, CA125 or HE4 alone. They also report
that HE4 has the highest specificity 92 %, better than
ROMA and CA125, 83.8 and 66.7 %, respectively.
This is, however, limited by the subjective assessment in
ultrasound examination, which is effective only when it is
performed by experienced clinician. Biomarker analysis is
more readily available to less experienced centers. HE4
alone or in combination with CA125 should, therefore, be
used as an adjunct to less experienced sonographers.
Franchi et al. [23] also present the opinion that a combi-
nation of biomarkers could offer an aid to less experienced
sonographers in the preoperative triage of adnexal masses.
We have shown, that in all analyzed tumors and, espe-
cially in the ‘‘probably benign’’ and ‘‘probably malignant’’
tumor groups, subjective ultrasound assessment has such
high prognostic values that adding biomarker evaluation
worsens diagnostic performance. In the group of ‘‘uncer-
tain’’ tumors, subjective assessment and biomarker
Table 5 The results of subjective ultrasonographic assessment in
groups of malignant and benign tumors





Probably benign (n = 70) 67 (95.7 %) 3 (4.3 %)
Uncertain, finally classified
as benign (n = 11)
10 (90.9 %) 1 (9.1 %)
Uncertain, finally classified
as malignant (n = 23)
6 (26.1 %) 17 (73.9 %)
Probably malignant (n = 41) 2 (4.9 %) 39 (95.1 %)
Bold values are statistically significant (P \ 0.0001)
Table 6 Net reclassification improvement calculated for the
assessment of second-line test benefits after subjective ultrasound
evaluation
Marker NRI P value




CA125 (cut-off = 35 IU/ml) -0.319 0.001
CA125 (cut-off = 95 IU/ml) -0.1765 0.018
Tumors classified as ‘‘probably
benign’’ and ‘‘probably malignant’’
HE4 -0.133 0.049
CA125 (cut-off = 35 IU/ml) -0.327 0.001
CA125 (cut-off = 95 IU/ml) -0.234 0.006
Tumors classified as ‘‘uncertain’’
HE4 -0.042 0.817
CA125 (cut-off = 35 IU/ml) 0.201 0.209
CA125 (cut-off = 95 IU/ml) 0.07 0.676
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evaluation both have low sensitivity and specificity, and in
this situation a search for new diagnostic tests is necessary.
In conclusion, our study confirms the significance of
subjective ultrasound assessment as the best single diag-
nostic test in malignancy prediction. After first-line sub-
jective evaluation with ultrasonography, a portion of
tumors still remains suspicious. In this situation, HE4 and
CA125 serum levels do not improve the diagnostic accu-
racy. However, HE4 evaluation satisfies clinical expecta-
tions for a test to be a diagnostic tool in assessing ovarian
tumors. The HE4 serum level has higher specificity,
accuracy and positive predictive value than CA125 espe-
cially at its standard cut-off. A higher cut-off for CA125 in
the group of ‘‘suspicious’’ ovarian tumors should be con-
sidered. These two biomarkers are complementary and may
be useful for less experienced sonographers. In some situa-
tions, assessment using all possible methods is still not enough
to identify the character of the disease and to exclude malig-
nancy. So far, none of the analyzed biochemical tests has
proved suitable as a second-line test in tumors where sub-
jective evaluation yielded an uncertain result.
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